ArticleResearch square2025
L2 epitope presenting virus-like particles as broad-spectrum vaccine candidates targeting genus beta human papillomaviruses.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Licensed human papillomavirus (HPV) vaccines do not target cutaneous ßHPV types implicated in skin cancer development in immunosuppressed individuals. The conserved N-terminus of minor capsid protein L2 contains cross-neutralization epitopes, offering the opportunity to develop broad-spectrum vaccine candidates. A sequential immunization strategy using N-terminal L2 fragments of five ßHPVs induced type-common humoral immunity. Four monoclonal antibodies (mAb) were generated that cross-neutralized multiple ßHPV types and conferred in vivo protection against potentially oncogenic HPV5/38/24. MAb epitopes were inserted individually into the DE-surface loop of HPV16 L1 virus-like particles (VLP). Immunizations with chimeric VLPs induced cross-neutralizing antibodies against multiple ßHPV types and conferred in vivo protection against HPV5 infection. Chimeric VLPs displaying ßHPV-L2 cross-neutralizing epitopes are promising broad-spectrum vaccine candidates against the plethora of ßHPVs. Immunization of patients prior to immunosuppression may reduce the burden of ßHPV infection and thus lower their highly increased risk to develop keratinocytic skin cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.